Activation of Nuclear Factor-кB in Sepsis and ARDS

  • J. W. Christman
  • T. S. Blackwell
  • M. P. Clark
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1997)

Abstract

Cytokines are widely believed to mediate the pathophysiology of the systemic inflammatory response syndrome (SIRS) which is associated with sepsis syndrome and the acute respiratory distress syndrome (ARDS) [1]. Cytokines are protein mediators that function as communication molecules by signaling diverse cellular responses. Once thought to be the exclusive product of immune cells, we now realize that both immune and non-immune cells can be stimulated to synthesize and release cytokines. After release, cytokines can act either locally or at a distant site reached through the circulation. Cytokines bind to specific signal-transducing receptors that are located on the cell of origin (autocrine), cells in the immediate vicinity of the cell of origin (paracrine), or on distant cells (endocrine). Receptor binding of cytokines initiates signal transduction through the generation of second messages which result in intracellular signals that include phosphorylation and dephosphorylation of important enzymes, and expression or deactivation of gene products that influence cellular behavior.

Keywords

Placebo Saccharide Glutathione Corticosteroid Polysaccharide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Christman JW, Rinaldo JE (1997) Adult respiratory distress syndrome: Pathogenesis. In: Fishman AP (ed) Pulmonary diseases and disorders, 3rd edn. McGraw Hill, New York (in press)Google Scholar
  2. 2.
    Van Zee KJ, DeForge LE, Fischer E, et al (1991) IL-8 in septic shock, endotoxemia, and after IL-1 administration. J Immunol 146: 3478–3482PubMedGoogle Scholar
  3. 3.
    Christman JW, Holden EP, Blackwell TS (1995) Strategies for blocking the systemic effects of cytokines in sepsis syndrome. Grit Care Med 23: 955–964CrossRefGoogle Scholar
  4. 4.
    Bernard GR, Luce JM, Sprung CL, et al (1987) High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317: 1565–1570PubMedCrossRefGoogle Scholar
  5. 5.
    Abraham E, Park YC, Covington P, Conrad SA, Schwartz M (1996) Liposomal prostaglandin El in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 24: 10–15PubMedCrossRefGoogle Scholar
  6. 6.
    Cohen J, Carlet J, for the INTERSEPT study group (1996) INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit Care Med 24: 1431–1440Google Scholar
  7. 7.
    Fisher CI Jr, Dhainault JF, Pribble JP (1994) Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results of a randomized, double blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Study Group. JAMA 27: 1836–1843CrossRefGoogle Scholar
  8. 8.
    Fisher CJ Jr, Agosti JM, Opal SM, et al (1996) Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 334: 1697–1702PubMedCrossRefGoogle Scholar
  9. 9.
    Bone RC, Balk RA, Fein AM, et al (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 23: 994–1006PubMedCrossRefGoogle Scholar
  10. 10.
    Blackwell TS, Christman JW (1996) Sepsis and cytokines: Current status. Br J Anaesth 77: 110–117PubMedCrossRefGoogle Scholar
  11. 11.
    Goodman RB, Strieter RM, Steinberg KP, et al (1997) Inflammatory cytokines in patient with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med (in press)Google Scholar
  12. 12.
    Miller EJ, Cohen AB, Matthay MA (1996) Increased interleukin-8 concentration in the pulmonary edema fluid of patient with acute respiratory distress syndrome from sepsis. Crit Care Med 24: 1448–1454PubMedCrossRefGoogle Scholar
  13. 13.
    Torre S, Zeroli C, Ciola M, et al (1993) Levels of interleukin-8 in patients with adult respiratory distress syndrome. J Infect Dis 67: 505–506CrossRefGoogle Scholar
  14. 14.
    Folkesson HG, Matthay MA, Hebert CA, Broaddus VC (1995) Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8-dependent mechanisms. J Clin Invest 96: 107–116PubMedCrossRefGoogle Scholar
  15. 15.
    Ulich TR, Howard SC, Remick DG, et al (1995) Intratracheal administration of endotoxin and cytokines. VI. Antiserum to CINC inhibits acute inflammation. Am J Physiol 268: L245 - L250PubMedGoogle Scholar
  16. 16.
    Schmitz ML, Baeuerle PA (1995) Multi-step activation of NF-kappa B/Rel transcription factors. Immunobiology 193: 116–127PubMedCrossRefGoogle Scholar
  17. 17.
    Ohmori Y, Fukumoto S, Hamilton TA (1995) Two structurally distinct kappa B sequence motifs cooperatively control LPS-induced KC gene transcription in mouse macrophages. J Immunol 155: 3593–3600PubMedGoogle Scholar
  18. 18.
    Schreck R, Albermann K, Baeuerle PA (1992) Nuclear factor kappa B: An oxidative stress-responsive transcription factor of eukaryotic cells. Free Rad Res Comm 17: 221–237CrossRefGoogle Scholar
  19. 19.
    Blackwell TS, Holden EP, Blackwell TR, Christman BW, Christman JW (1996) Activation of NF-KB in rat lungs by treatment with endotoxin: Modulation by treatment with N-acetylcysteine. J Immunol 157: 1630–1637PubMedGoogle Scholar
  20. 20.
    Schwartz MD, Moore EE, Moore FA, et al (1996) Nuclear factor-KB is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Grit Care Med 24: 1285–1292CrossRefGoogle Scholar
  21. 21.
    Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C (1994) N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 105: 190–194PubMedCrossRefGoogle Scholar
  22. 22.
    Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO (1992) Antioxidant treatment with Nacetylcysteine during adult respiratory distress syndrome: A prospective, randomized, placebo-controlled study. Crit Care Med 20: 918–923PubMedCrossRefGoogle Scholar
  23. 23.
    Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS (1995) Role of transcriptional activation of I-kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 70: 283–286CrossRefGoogle Scholar
  24. 24.
    Auphan N, DiDonato JA, Rosette C, Helmberg A, Karins M (1995) Immunosuppression by glucocorticodis: Inhibition of NF-kappa B activity through induction of I-kappa B synthesis. Science 70: 286–290CrossRefGoogle Scholar
  25. 25.
    Ziegler-Heitbrock HWL (1995) Molecular mechanism in tolerance to lipopolysaccharide. J Inflammation 45: 13–25Google Scholar
  26. 26.
    McCall CE, Grosso-Wilmoth LM, LaRue K, Guzman RN, Cousart SL (1993) Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest 91: 853–861PubMedCrossRefGoogle Scholar
  27. 27.
    Granowitz EV, Porat R, Mier JW, et al (1993) Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol 151: 1637–1645PubMedGoogle Scholar
  28. 28.
    Muller JM, Ziegler-Heitbrock JWL, Bauerle P (1993) Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 187: 233–256PubMedCrossRefGoogle Scholar
  29. 29.
    Zuckerman SH, Evans GF (1992) Endotoxin tolerance: In vivo regulation of tumor necrosis factor and interleukin-1 synthesis is at the transcriptional level. Cellular Immunology 140: 513–519PubMedCrossRefGoogle Scholar
  30. 30.
    Ziegler-Heitbrock HWL, Wedel A, Schraut W, et al (1994) Tolerance to lipopolysaccharide involves mobilization of nuclear factor kappa B with predominance of p50 homodimers. J Biolog Chem 269: 17001–17004Google Scholar
  31. 31.
    Carpati CM, Astiz ME, Rachow EC, Kim JW, Kim YB, Weil MH (1992) Monophosphoryl Lipid A attenuates the effect of endotoxin shock in pigs. J Lab Clin Med 119: 346–353PubMedGoogle Scholar
  32. 32.
    Astiz ME, Saha DC, Brooks K, Carpati CM, Rackow EC (1993) Comparison of the induction of endotoxin tolerance in endotoxemia and peritonitis by monophosphoryl Lipid A and lipopolysaccharide. Circ Shock 39: 194–198PubMedGoogle Scholar
  33. 33.
    Astiz ME, Rackow EC, Still JG, et al (1995) Pretreatment of normal humans with monophosphoryl Lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized, controlled trial. Crit Care Med 23: 9–17PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • J. W. Christman
  • T. S. Blackwell
  • M. P. Clark

There are no affiliations available

Personalised recommendations